Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems

Feb 12, 2021AAPS PharmSciTech

Improving Glioblastoma Treatments with Nanoparticle Delivery Systems

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗

Abstract

Nanoparticle-mediated delivery systems may improve treatment outcomes for glioblastoma multiforme (GBM) by enhancing drug accumulation at tumor sites.

Current FDA-approved treatments for GBM include surgery, radiation, and chemotherapy, but new approaches are being explored.
Nanoparticles (NPs) can potentially cross the blood-brain barrier through mechanisms such as adsorptive-mediated transcytosis and receptor-mediated transcytosis.
NPs may facilitate local sustained release of tumor-killing drugs directly at or near GBM tumors.
Using multitargeting NPs with specific ligands may reduce off-target effects and increase drug action at tumor sites.
Advances in understanding GBM's molecular mechanisms have led to improved efficacy of drug delivery using targeted nanoparticle systems.

AI simplified

Glioblastoma multiforme (GBM) is the most aggressive type of malignant brain tumor. Current FDA-approved treatments include surgical resection, radiation, and chemotherapy, while hyperthermia, immunotherapy, and most relevantly, nanoparticle (NP)-mediated delivery systems or combinations thereof have shown promise in preclinical studies. Drug-carrying NPs are a promising approach to brain delivery as a result of their potential to facilitate the crossing of the blood-brain barrier (BBB) via two main types of transcytosis mechanisms: adsorptive-mediated transcytosis (AMT) and receptor-mediated transcytosis (RMT). Their ability to accumulate in the brain can thus provide local sustained release of tumoricidal drugs at or near the site of GBM tumors. NP-based drug delivery has the potential to significantly reduce drug-related toxicity, increase specificity, and consequently improve the lifespan and quality of life of patients with GBM. Due to significant advances in the understanding of the molecular etiology and pathology of GBM, the efficacy of drugs loaded into vectors targeting this disease has increased in both preclinical and clinical settings. Multitargeting NPs, such as those incorporating multiple specific targeting ligands, are an innovative technology that can lead to decreased off-target effects while simultaneously having increased accumulation and action specifically at the tumor site. Targeting ligands can include antibodies, or fragments thereof, and peptides or small molecules, which can result in a more controlled drug delivery system compared to conventional drug treatments. This review focuses on GBM treatment strategies, summarizing current options and providing a detailed account of preclinical findings with prospective NP-based approaches aimed at improving tumor targeting and enhancing therapeutic outcomes for GBM patients.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (HTML) ↗

Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief